Signal #149970 · SEC 8-K
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
$ATYR triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +1.5/10). Headline: aTyr Pharma Reports Q3 2026 Results, FDA Alignment on Phase 3 Study. Key points: - Reached FDA alignment on proposed Phase 3 study design of efzofitimod in pulmonary sarcoidosis - Cash and investments stood at $50.3M as of Q3 2026, providing runway into late 2028 - Company actively prioritizing strategic partnerships to advance Phase 3 development
After the SEC 8-K for $ATYR, observed market reaction: T0 price $6.03. Past moves do not guarantee future results.
Stock Catalyst AI pushes real-time SEC 8-K alerts for $ATYR via Telegram and the VIP Web Terminal from €10/month.